Ocugen vs Prime Medicine
Ocugen and Prime Medicine are similar in size: $4.4m and $4.6m of revenue in their latest fiscal years. Prime Medicine grew faster (55.3% against 8.8%). Ocugen kept more of each dollar of sales as profit: a net margin of -1537.4% against -4342.4%.
| Latest fiscal year | OcugenOCGN, 2025 | Prime MedicinePRME, 2025 |
|---|---|---|
| Revenue | $4.4m | $4.6m |
| Revenue growth | 8.8% | 55.3% |
| Net income | −$67.8m | −$201m |
| Operating margin | -1425.7% | -4498.1% |
| Net margin | -1537.4% | -4342.4% |
| Return on equity | — | -146.8% |
| Free cash flow | −$57.1m | −$167m |
| Cash | $18.6m | $63.0m |
| Total debt | $31.5m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 116 | 146 |
| Market value | $253m | $807m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 1 buys, 4 sales | 0 buys, 0 sales |